WO1993013777A1 - Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy - Google Patents
Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy Download PDFInfo
- Publication number
- WO1993013777A1 WO1993013777A1 PCT/US1993/000241 US9300241W WO9313777A1 WO 1993013777 A1 WO1993013777 A1 WO 1993013777A1 US 9300241 W US9300241 W US 9300241W WO 9313777 A1 WO9313777 A1 WO 9313777A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myopia
- eye
- receptors
- animal
- pyridobenzodiazepinones
- Prior art date
Links
- 230000004329 axial myopia Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 18
- MGDDXKBVXQCWER-UHFFFAOYSA-N pyrido[2,3-i][1,2]benzodiazepin-3-one Chemical class N1=NC(=O)C=CC2=CC=C(N=CC=C3)C3=C21 MGDDXKBVXQCWER-UHFFFAOYSA-N 0.000 title abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 title description 18
- 230000001022 anti-muscarinic effect Effects 0.000 title description 3
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 210000001110 axial length eye Anatomy 0.000 claims abstract 4
- 230000002159 abnormal effect Effects 0.000 claims description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004373 acetylcholine Drugs 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 34
- 230000004379 myopia Effects 0.000 description 31
- 208000001491 myopia Diseases 0.000 description 31
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 18
- 229960004633 pirenzepine Drugs 0.000 description 18
- 229930003347 Atropine Natural products 0.000 description 16
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 16
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 16
- 229960000396 atropine Drugs 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- LPLNSPKKMWHFAU-UHFFFAOYSA-N 11-(1-methylpiperidine-3-carbonyl)-6h-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound C1N(C)CCCC1C(=O)N1C2=NC=CC=C2C(=O)NC2=CC=CC=C21 LPLNSPKKMWHFAU-UHFFFAOYSA-N 0.000 description 14
- HPKYRXAEGNUARA-UHFFFAOYSA-N 11-(1-methylpiperidine-4-carbonyl)-6h-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound C1CN(C)CCC1C(=O)N1C2=NC=CC=C2C(=O)NC2=CC=CC=C21 HPKYRXAEGNUARA-UHFFFAOYSA-N 0.000 description 14
- 229950007677 nuvenzepine Drugs 0.000 description 14
- 229950005803 rispenzepine Drugs 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 210000001525 retina Anatomy 0.000 description 8
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 7
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003149 muscarinic antagonist Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 201000009487 Amblyopia Diseases 0.000 description 5
- 210000004240 ciliary body Anatomy 0.000 description 5
- 229940124570 cycloplegic agent Drugs 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 229940012356 eye drops Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000004323 axial length Effects 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 239000000634 cycloplegic agent Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004515 progressive myopia Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000017925 CHRM3 Human genes 0.000 description 3
- 101150060249 CHRM3 gene Proteins 0.000 description 3
- 102000009660 Cholinergic Receptors Human genes 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 206010020675 Hypermetropia Diseases 0.000 description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000004423 myopia development Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000001722 neurochemical effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- YZPAKBGVJIVPEU-UHFFFAOYSA-N 1,2-benzodiazepin-6-one Chemical compound N1=NC=CC=C2C(=O)C=CC=C21 YZPAKBGVJIVPEU-UHFFFAOYSA-N 0.000 description 2
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000017926 CHRM2 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 101150012960 Chrm2 gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000003500 cycloplegic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 1 -ethylpiperidin-4-yl Chemical group 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- WWJHRSCUAQPFQO-UHFFFAOYSA-M 4-DAMP methiodide Chemical compound [I-].C1C[N+](C)(C)CCC1OC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 WWJHRSCUAQPFQO-UHFFFAOYSA-M 0.000 description 1
- MZDYABXXPZNUCT-OAQYLSRUSA-N AF-DX 384 Chemical compound CCCN(CCC)C[C@H]1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 MZDYABXXPZNUCT-OAQYLSRUSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 231100000938 Guinea Pig Maximization Test Toxicity 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 201000000255 cycloplegia Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000004315 low visual acuity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HBPSMMXRESDUSG-UHFFFAOYSA-N piperidine;hydroiodide Chemical compound I.C1CCNCC1 HBPSMMXRESDUSG-UHFFFAOYSA-N 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004256 retinal image Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to control of ocular development in general and, more particularly, to the treatment of the eye to prevent and/or arrest the development of myopia (nearsightedness).
- Myopia afflicts approximately 25% of the world's population. In particular, myopia afflicts 15% to 75% of the youth of the world, depending upon race, geographic distribution and level of education. Approximately one-half of all cases are classifiable as axial myopia, where there is an elongation of the eye along the visual axis.
- the human eye At birth, the human eye is about two-thirds of the size of an adult eye. This is relatively short in the direction of the visual axis, or axial, direction. As a result, children tend to be far-sighted.
- Myopia is not a trivial maldevelopment of the eye. In its pathologic form, the sclera continues to grow as the retina stretches and degenerates resulting in permanent blindness. The surgical therapies attempted for this condition are drastic and often unsuccessful.
- Cycloplegics are topically administered drugs that relax the ciliary muscle of the eye, which is the muscle that focuses the eye by controlling lens dimensions.
- the classic cycloplegic drug is the belladonna alkaloid atropine, available for over a century.
- Atropine is a long-acting non ⁇ specific antimuscarinic agent that antagonizes the action of the neurotransmitter acetylchofme (ACh) at autonomic effector cells innervated by postganghonic cholinergic nerves of the parasympathetic nervous system.
- ACh neurotransmitter acetylchofme
- Atropine has not been widely used for slowing the progression of myopia due to drug effects including glare from pupillary dilation, and inhibition of ocular focusing that impairs near visual work like reading.In addition to the discomfort to the patient, there is evidence that long-term use of atropine or other long-term cycloplegics can harm the retina when it is exposed to bright light.
- the phenomenon of an animal's vision process apparently contributes to the feedback mechanism by which postnatal ocular growth is normally regulated and refractive error is determined. This indicates that this mechanism is neural and likely originates in the retina.
- R. A. Stone, et al. have found a method of controlling the abnormal postnatal growth of the eye of a maturing animal, which comprises controlling the presence of a neurochemical, its agonist or antagonist, which neurochemical is found to be changed under conditions during maturation leading to abnormal axial length. Therein it is disclosed that in experimental animals such as chicks or monkeys subjected to ocular image deprivation ordinarily leading to the development of myopia, the metabolism of certain retinal neurochemicals is altered leading to changes in retinal concentrations thereof.
- retinal concentrations of dopamine were found to be reduced during such image deprivation and the ocular administration of a dopamine-related agent, e.g., apOmorphine, a dopamine agonist, was found to inhibit or actually prevent the axial enlargement of the eye under conditions ordinarily leading to such enlargement.
- a dopamine-related agent e.g., apOmorphine, a dopamine agonist
- Cholinergic receptors are proteins embedded in the wall of a cell that respond to the chemical acetylcholine. These receptors are broadly broken down into nicotinic and muscarinic receptors. In this respect, it is now known that the muscarinic receptors are not all of one type. Recent findings show that there are at least five, if not more, types of cholinergic muscarinic receptors (types Mj through M5). Type Mj receptors are those present in abundance and thought to be enriched in the brain neural tissue and neural ganglia. Other receptors are concentrated in other tissues, such as in heart, smooth muscle tissue, or glands.
- pirenzepine (Gastrozepin, LS 519) 5,l l-Dihydro-l l-[4-methyl-l-piperazinyl)acetyl]-6H- pyrido[2,3-b][l,4]benzodiazepin-6-one, and its dihydrochloride, are anticholinergic, antmuscarinic, and relatively selective for M ] ⁇ receptors.
- 4-DAMP 4-diphenyIacetoxy-N- methylpiperadine methiodide
- smooth muscle ordinarily called M3 type but variously called type M2 or M3, as the current classification of receptors is in flux).
- Atropine discussed above as a cycloplegic agent, is a non-specific antagonist for all types of cholinergic muscarinic receptors.
- Pirenzepine being primarily an M j antagonist, inhibits axial elongation, but is far less effective at pupil dilation than atropine or another cycloplegic agent. This makes it possible to suppress the development of myopia without dilating the pupil and paralyzing the accommodation activity of the ciliary body.
- Pirenzepine however, has a disadvantage.
- the administration of a drug topically into the eye of a developing child for a long period of time makes it desireable to have a minimal likelihood of sensitization of the eye.
- Pirenzepine tests positive in sensitization assays.
- the invention is a method of using a compound of the formula:
- R is defined as before, that is piperidine substituted by C j _5 alkyl.
- the reaction is carried out in polar solvents such as dimethylf ormamide and dimethylsulf oxide in the presence of bases such as triethylamine, alkaline hydroxides and alkaline carbonates at temperatures ranging from room temperature to 150°C, with reaction times ranging from 2 to 24 hours.
- Representative pharmaceutically acceptable salts include, for example, hydrochloride and maleate. Salts are generally prepared as acid addition salts by combining the core compound with one-to-three equivalents of an appropriate acid in an inert solvent. The salt is then recovered by solvent evaporation or by filtration if the salt precipitates spontaneously, or by precipitation using a co-solvent or a non-polar co- solvent followed by filtration.
- pharmaceutically effective amount shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or organ that is being sought by a veterinarian or physician.
- alkyl shall mean linear straight or branched chain alkane or alkene.
- substituted shall be deemed to include multiple degrees of substitution by a named substituent.
- the compounds used in the method of the invention can be prepared readily according to the following detailed examples using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but which are not mentioned in greater detail. Additional background information is taught in U.S. Patent No. 4,556,653, the entire disclosure of which is incorporated herein by reference.
- the chloride of l-methylpiperidine-3-carboxylic acid hydrochloride (4.7g) is added to a solution of 5,l l-dihydro-6H- pyrido[2,3-b][l,4] benzodiazepin-6-one (5g) and triethylamine (7.5ml) in dimethylformamide (200ml).
- the reaction mixture is heated to 90°C for 24 hours.
- the chloride of l-methylpiperidine-4-carboxylic acid hydrochloride (4.7g) was added to a solution of 5,l l-dihydro-6H- pyrido[2,3-b][l,4] benzodiazepin-6-one (5g) and triemylamine (7.5ml) in dimethylformamide (200ml). The reaction mixture was heated to 90°C for 24 hours.
- the muscarinic agents for use in this invention are those relatively selective in blocking the Mj type receptors and which are relatively less selective for the type M3 smooth muscle receptors. Relative affinities for M1-M5 receptors were determined using the following assay.
- M j receptors in rat cerebral cortex were labeled with ⁇ H-pirenzepine
- ⁇ H-AFDX-384 labeled M2 receptors in rat heart and M3 receptors in rabbit iris + ciliary body (minus ciliary processes which contain M j receptors) were labeled with - ⁇ - QNB.
- Scatchard analysis revealed that one population of binding sites was labeled in each tissue and the following Kd and Bmax values were obtained: cortex (2.36 nM, 1781 fmol/mg protein), heart (5.77 nM, 164 fmol/mg protein) and iris + ciliary body (24.5 pM and 210 fmol/mg protein).
- Ki values in the three binding assays were obtained for atropine, rispenzepine, pirenzepine and nuvenzepine.
- the most potent of the agents at M ⁇ binding sites was atropine with a Ki value of 0.13 nM.
- Pirenzepine, nuvenzepine and rispenzepine possessed Ki values of
- Atropine was the most potent of the antagonists at M2 receptors possessing a Ki of 0.82 nM while pirenzepine (532 nM), nuvenzepine (248 nM) and rispenzepine
- Mi ⁇ H Pirenzepine binding, rat cerebral cortex.
- M 2 H AFDX-384 binding, rat heart.
- M3 ⁇ H-QNB binding, rabbit iris + ciliary body (minus ciliary processes).
- the affinity and relative affinity of muscarinic antagonists for M1-M5 receptors can be determined by other means known in the art. For example, see Buckley, et al., Molecular
- vas deferens of the guinea pig which has an M ⁇ sensitivity. First it is set up so that its tension is measured and a known stimulator such as the Ml agonist McNeil A343 is given to change tension by a predictable amount. Under this condition, the predicted effect of the agonist is first carefully plotted and then the degree to which one or another antagonist blocks this agonist effect is measured.
- Form-deprivation myopia is induced in day-old White
- the guinea pig maximization test is required by the U.S. Food and Drug Administration of all drugs intended for ophthalmic administration.
- the test population for nuvenzepine and rispenzepine versus pirenzepine consisted of at least nine female Dunkin Hartley albino guinea pigs between 300 and 500g, with 10 control animals.
- Phase I which is the induction phase, on day 1 two intradermal injections at the highest generally tolerated concentration of the test material were administered in the shaved intercapsular area (0.1ml of the test agent in a 50:50 mixture of Freund's complete adjuvant and distilled water).
- Phase ⁇ which is the challenge phase, on day 22, 200mg of petrolatum was applied to the shaved right flank, while 200mg of test compound at the highest non-irritant concentration (micronized in petrolatum) was applied to the shaved left flank, with each application being occluded for 24 hours. Readings were taken on days 24 and 25, with grades assigned as follows:
- the refractive state of the eye is easily determined even in newborn infants by the use of a retinoscope, a handheld instrument. This objective measurement is performed after cycloplegia of the eye has been obtained by topical administration of cyclopentolate or atropine. Furthermore, the axial length of the eye can easily be measured using ultrasonography. Myopia becomes manifest as children reach the age of 7 to 12 years. Once identified, the myopia usually progresses until the eye completes development after the age of 14.
- pharmacologic therapy could be initiated to reduce the rate of progression. Therapy would be continued until the ocular development is completed. For most children, therapy would be initiated between the ages of 7 and 10 years and discontinued around the age of 14 years.
- Eye drops are typically made up at a concentration of active agent between about 0.5 and 2 percent in the ophthalmic medium.
- a 1% solution of rispenzepine or nuvenzepine in water would be a likely concentration for clinical use.
- Some constraints in formulation may exist having to do with pH and preservative. A pH of about 6.5 is expected to be acceptable as an ophthalmic drop and practical in terms of known solubility and stability of pyridobenzodiazepinones.
- pirenzepine is known to form very acidic solutions in physiological saline
- treatment with known compatible bases to bring the pH up to about 4.5 to 7.5 (preferably 6 or 6.5) is recommended.
- Phosphate buffering is also common for eye drops and is compatible with rispenzepine and nuvenzepine.
- a common regimen for application of eye drops is two to three times a day spaced evenly throughout waking hours. More effective agents may require fewer applications or enable the use of more dilute solutions.
- ointments and sohd inserts are now coming into increased use in clinical practice. They avoid problems of drug decomposition while delivering a defined amount of drug. It is, of course, also possible to administer the above described active agents in therapeutically effective amounts and dosages in pills, capsults, or other preparations of systemic administration.
- amblyopia is evidenced by poor visual acuity in the eye resulting in poor visual performance. Normally, visual acuity improves during maturation. It is known that amblyopia may occur in humans from unknown causes or as part of strabismus. It is possible that administration of therapeutically effective amounts and dosages of the muscarinic antagonists relatively selective in blocking the Mi cholinergic receptors, but less selective in blocking cholinergic receptors in smooth muscle cells, e.g.
- rispenzepine and nuvenzepine might prevent or inhibit the development of permanent or persistent amblyopia in maturing humans with decreased likelihood of sensitization of the eye. It is also possible that humans who have already developed amblyopia from other or even unknown causes might be aided by similar therapeutic treatment with the aforementioned agents.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82349592A | 1992-01-21 | 1992-01-21 | |
US823,495 | 1992-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993013777A1 true WO1993013777A1 (en) | 1993-07-22 |
Family
ID=25238929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/000241 WO1993013777A1 (en) | 1992-01-21 | 1993-01-12 | Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy |
Country Status (10)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737475A3 (en) * | 1989-06-21 | 1997-09-17 | Univ Pennsylvania | Treatment and regulation of eye development with a muscarinic antagonist |
WO1998030900A3 (en) * | 1997-01-06 | 1998-12-10 | Klaus Trier Aps | Screening method for compounds active in treating myopia and hypermetropia |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
JP6784407B2 (ja) * | 2015-04-24 | 2020-11-11 | 学校法人慶應義塾 | 近視予防剤及び近視進行抑制剤 |
GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
CN110308571B (zh) | 2015-09-15 | 2024-01-30 | 星欧光学股份有限公司 | 隐形眼镜产品 |
US12298602B2 (en) | 2015-09-15 | 2025-05-13 | Largan Medical Co., Ltd. | Multifocal contact lens and contact lens product |
US10845622B2 (en) | 2015-09-15 | 2020-11-24 | Largan Medical Co., Ltd. | Multifocal contact lens and contact lens product |
CN115414357B (zh) * | 2022-08-30 | 2023-09-22 | 天津医科大学眼科医院 | 一种酰胺类化合物在制备防治近视的药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125607A2 (en) * | 1983-05-17 | 1984-11-21 | DOMPE' FARMACEUTICI S.p.A. | Pyrido(1,5)benzodiazepinone derivatives and pharmacological activities thereof |
WO1990015604A1 (en) * | 1989-06-21 | 1990-12-27 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
-
1993
- 1993-01-12 WO PCT/US1993/000241 patent/WO1993013777A1/en not_active Application Discontinuation
- 1993-01-14 EP EP93300208A patent/EP0556947A1/en not_active Withdrawn
- 1993-01-15 IL IL104409A patent/IL104409A0/xx unknown
- 1993-01-18 JP JP5005813A patent/JPH0742231B2/ja not_active Expired - Lifetime
- 1993-01-18 TW TW082100297A patent/TW222583B/zh active
- 1993-01-18 CA CA002087510A patent/CA2087510A1/en not_active Abandoned
- 1993-01-20 AU AU31923/93A patent/AU3192393A/en not_active Abandoned
- 1993-01-20 ZA ZA93374A patent/ZA93374B/xx unknown
- 1993-01-20 ZA ZA1993374A patent/ZA93384B/xx unknown
- 1993-01-20 CN CN93100697A patent/CN1074606A/zh active Pending
- 1993-01-20 MX MX9300250A patent/MX9300250A/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125607A2 (en) * | 1983-05-17 | 1984-11-21 | DOMPE' FARMACEUTICI S.p.A. | Pyrido(1,5)benzodiazepinone derivatives and pharmacological activities thereof |
WO1990015604A1 (en) * | 1989-06-21 | 1990-12-27 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
Non-Patent Citations (2)
Title |
---|
EUROPEAN JOURNAL OF PHARMACOLOGY vol. 179, no. 1-2, 10 April 1990, pages 89 - 96 BAROCELLI E. ET AL 'EFFECTS OF TWO NEW PIRENZEPINE ANALOGS ON THE CONTRACTILE RESPONSE OF THE GUINEA-PIG OESOPHAGEAL MUSCULARIS MUCOSAE TO ACETYLCHOLINE, BETHANECOL, HISTAMINE AND HIGH POTASSIUM' * |
EXPERIMENTAL EYE RESEARCH vol. 52, no. 6, June 1991, pages 755 - 758 STONE R.A. ET AL 'MUSCARINIC ANTAGONIST EFFECTS ON CHICK MYOPIA' * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737475A3 (en) * | 1989-06-21 | 1997-09-17 | Univ Pennsylvania | Treatment and regulation of eye development with a muscarinic antagonist |
WO1998030900A3 (en) * | 1997-01-06 | 1998-12-10 | Klaus Trier Aps | Screening method for compounds active in treating myopia and hypermetropia |
US6710051B1 (en) * | 1997-01-06 | 2004-03-23 | Klaus Trier Aps | Screening method |
Also Published As
Publication number | Publication date |
---|---|
JPH06206820A (ja) | 1994-07-26 |
AU3192393A (en) | 1993-07-22 |
MX9300250A (es) | 1993-07-01 |
ZA93374B (en) | 1993-08-23 |
EP0556947A1 (en) | 1993-08-25 |
IL104409A0 (en) | 1993-05-13 |
TW222583B (enrdf_load_html_response) | 1994-04-21 |
JPH0742231B2 (ja) | 1995-05-10 |
ZA93384B (en) | 1993-08-23 |
CA2087510A1 (en) | 1993-07-22 |
CN1074606A (zh) | 1993-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0737475B1 (en) | Use of a muscarinic antagonist in the manufacture of a medicament for the treatment and control of ocular development | |
AU2021356807B2 (en) | Use of penehyclidine in treatment or prevention of vision-impairing eye diseases | |
WO1993013777A1 (en) | Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy | |
US5637604A (en) | Treatment and control of ocular development | |
JPH078805B2 (ja) | 眼の発育の神経ペプチド制御 | |
HK1007681B (en) | Use of pirenzepine, telenzepine oder o-methoxy-sila-hexocyclium in the manufacture of a medicament for the treatment and control of ocular development | |
CN111349036B (zh) | 一种格隆溴铵的替代物及其制备方法和医药用途 | |
US5952338A (en) | Agent for prophylaxis and treatment of disturbance of visual function | |
AU677860B2 (en) | Composition for prophylaxis and treatment of myopia | |
JP3066561B2 (ja) | 近視予防・治療剤 | |
CN116459251B (zh) | 一种含西维美林的眼用制剂及其制备方法和应用 | |
US5461052A (en) | Prevention of myopia by tricyclic compounds | |
CA2369054C (en) | Treatment and control of ocular development | |
KR20000013487A (ko) | 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물 | |
KR19990080875A (ko) | 갈라민을 유효성분으로 하는 근시예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BB BG BR FI HU KR LK MG MN MW NO NZ PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: PL |
|
WA | Withdrawal of international application | ||
NENP | Non-entry into the national phase |
Ref country code: CA |